KalVista Pharmaceuticals (KALV) Interest & Investment Income (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Interest & Investment Income of $1.8 million in Q3 2025, down 7.18% quarter-over-quarter from $2.0 million in Q2 2025, and up 9.28% year-over-year from $1.7 million in Q3 2024.
KalVista Pharmaceuticals' Interest & Investment Income history runs 12 years deep, the most recent figure standing at $1.8 million for Q3 2025.
- In Q3 2025, Interest & Investment Income rose 9.28% year-over-year to $1.8 million; the TTM figure through Jul 2025 stood at $6.9 million (up 47.7% YoY), while the FY2025 annual figure was $6.4 million, up 65.17% from the prior year.
- Interest & Investment Income came in at $1.8 million for Q3 2025 at KalVista Pharmaceuticals, down from $2.0 million in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $2.0 million in Q2 2025 to a low of $137000.0 in Q1 2021.
- A 5-year average of $808777.8 and a median of $708000.0 in 2023 frame the typical range for Interest & Investment Income.
- Across the five-year window, Interest & Investment Income slumped 63.17% in 2021 and surged 281.4% in 2023, its largest moves.
- KalVista Pharmaceuticals' Interest & Investment Income stood at $290000.0 in 2021, then surged by 54.83% to $449000.0 in 2022, then surged by 72.83% to $776000.0 in 2023, then soared by 74.87% to $1.4 million in 2024, then soared by 36.26% to $1.8 million in 2025.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $1.8 million, $2.0 million, and $1.4 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 1.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 1.85 Mn |
| Apr 30, 2025 | 1.99 Mn |
| Oct 31, 2024 | 1.36 Mn |
| Jul 31, 2024 | 1.69 Mn |
| Apr 30, 2024 | 1.51 Mn |
| Jan 31, 2024 | 684,000.00 |
| Oct 31, 2023 | 776,000.00 |
| Jul 31, 2023 | 923,000.00 |
| Apr 30, 2023 | 808,000.00 |
| Jan 31, 2023 | 732,000.00 |
| Oct 31, 2022 | 449,000.00 |
| Jul 31, 2022 | 242,000.00 |
| Apr 30, 2022 | 268,000.00 |
| Jan 31, 2022 | 258,000.00 |
| Oct 31, 2021 | 290,000.00 |
| Jul 31, 2021 | 274,000.00 |
| Apr 30, 2021 | 314,000.00 |
| Jan 31, 2021 | 137,000.00 |
| Oct 31, 2020 | 193,000.00 |
| Jul 31, 2020 | 259,000.00 |
| Apr 30, 2020 | 363,000.00 |
| Jan 31, 2020 | 372,000.00 |
| Oct 31, 2019 | 505,000.00 |
| Jul 31, 2019 | 590,000.00 |
| Apr 30, 2019 | 381,000.00 |
| Jan 31, 2019 | 723,000.00 |
| Oct 31, 2018 | 204,000.00 |
| Jul 31, 2018 | 89,000.00 |
| Apr 30, 2018 | 65,000.00 |
| Jan 31, 2018 | 14,000.00 |
| Oct 31, 2017 | 1,000.00 |
| Jul 31, 2017 | 2,000.00 |
| Apr 30, 2017 | 5,000.00 |
| Jan 31, 2017 | 7,000.00 |
| Oct 31, 2016 | 10,000.00 |
| Jul 31, 2016 | 14,000.00 |
| Mar 31, 2016 | 12,000.00 |
| Dec 31, 2015 | 1,000.00 |
| Sep 30, 2015 | 2,000.00 |
| Jun 30, 2015 | 2,000.00 |
| Mar 31, 2015 | 553,000.00 |
| Sep 30, 2014 | 1,000.00 |
| Jun 30, 2014 | 1,000.00 |
| Mar 31, 2014 | -79,000.00 |